Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenabasum phase 2 trial in cystic fibrosis
NL-OMON48813Phase 2Active, not recruiting
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lenabasum in cystic fibrosis (CF) (3 arms), sponsored by Corbus Pharmaceuticals Holdings, Inc. Primary endpoint: Rate of pulmonary exacerbations using primary definition. Started Aug 2019; status: active, not recruiting.
02
Drugs
lenabasum
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON48813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48813.